Standard treatments for brain and spinal cord tumors, like chemotherapy and surgery, often fall short due to their difficult access and aggressive nature. Dr. Jay Read, a clinical assistant professor of pediatrics and pediatric hematology-oncology, is leading the way with a groundbreaking new therapy—Chimeric Antigen Receptor (CAR) T-cell therapy. With Phase I trials now underway, U-M is exploring how this innovative treatment could offer hope for patients with inoperable brain tumors. Read on to discover how this cutting-edge approach could change the future of cancer treatment.
